Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B

Published:2018-03 Issue:3 Volume:68 Page:431-440
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Janssen Harry L.A.,Brunetto Maurizia R.,Kim Yoon Jun,Ferrari Carlo,Massetto Benedetta,Nguyen Anh-Hoa,Joshi Adarsh,Woo Jacky,Lau Audrey H.,Gaggar Anuj,Subramanian G. Mani,Yoshida Eric M.,Ahn Sang Hoon,Tsai Naoky C.S.,Fung Scott,Gane Edward J.

Publisher

Elsevier BV

Subject

Hepatology

Reference37 articles.

1. Razavi-Shearer-Spink D. Global Estimate of Hepatitis B and Hepatitis Delta. Polaris Observatory 2016;http://www.polarisobservatory.com/.

2. World Health Organization. Draft global health sector strategies: Viral hepatitis, 2016–2021. SIXTY-NINTH WORLD HEALTH ASSEMBLY. http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1; 2016.

3. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection;Bertoletti;Gut,2012

4. The molecular basis of the failed immune response in chronic HBV: therapeutic implications;Maini;J Hepatol,2010

5. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013;Lancet,2015

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’;Canadian Liver Journal;2024-08-28

2. Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod;Clinical and Translational Science;2024-08

3. Dysfunction of dendritic cells in tumor microenvironment and immunotherapy;Cancer Communications;2024-07-25

4. Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections;Antiviral Research;2024-06

5. TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism;Gut;2024-05-02